title: Distribution of globin genes and histone variants in micrococcal nuclease-generated subfractions of chromatin from Friend erythroleukemia cells at different malignant states.
abstract: The distribution of the alpha and beta-globin genes and histone variants was examined in micrococcal nuclease-generated chromatin fractions of three Friend murine erythroleukemia cell types differing in malignant potential and inducibility to erythroid differentiation. A preferential concentration of globin gene sequences, as compared to satellite DNA, was noted in a physiological salt-soluble, histone H1-depleted, mononucleosomal chromatin fraction (Sup 120) in all Friend cell types, even those in which the globin gene was not capable of transcriptional activation by chemical induction. The level of globin gene enrichment in the Sup 120 fraction was highest in the most malignant and inducible cell type. The chemical induction of erythroid differentiation in this cell line did not change the distribution of globin genes in the chromatin fractions. The Sup 120 chromatin fraction prepared from mouse brain nuclei was not enriched in globin genes. Besides the previously reported low H2A. 1/H2A.2 ratio [Blankstein and Levy: Nature 260:638-640, 1976], chromatin from the most tumorigenic cell type showed the lowest H2B.2 to H2B.1 ratio, highest levels of histone H4 acetylation, and the most pronounced change in relative amounts of two major electrophoretic bands of histone H1 variants as compared to the less malignant cell types. The histone variant content of the micrococcal nuclease-generated chromatin fractions from the three Friend cell types reflected the core histone variant differences for the respective intact nuclei. However, the electrophoretic separation of mononucleosomes by size revealed several classes with different H2A variant ratios. The results demonstrate the existence of structural differences in globin gene and histone variants in erythroleukemia cell chromatin associated with distinguishable phenotypes during malignant cell progression.
authors.affiliation: Department of Medicine and Molecular Biology, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111.
authors.forename: K E
authors.initials: KE
authors.lastname: Leonardson
authors.forename: S B
authors.initials: SB
authors.lastname: Levy
mesh_terms: D000107:Acetylation; D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D002843:Chromatin / Q000302:isolation & purification / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000032:analysis*; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D005622:Friend murine leukemia virus; D014644:Genetic Variation; D005914:Globins / Q000235:genetics*; D006657:Histones / Q000235:genetics*; D004915:Leukemia, Erythroblastic, Acute / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008836:Micrococcal Nuclease / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D002843:Chromatin; D004273:DNA, Neoplasm; D006657:Histones; D005914:Globins; D008836:Micrococcal Nuclease; D004121:Dimethyl Sulfoxide